
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported positive topline results from the Phase 2 proof-of-concept study of its lead candidate LX9211 in painful diabetic neuropathy.
The RELIEF-DPN-1 is the first of two Phase 2 proof-of-concept study designed to evaluate LX9211 in patients with neuropathic pain.